RESUMO
Oxidizability of isolated low density lipoprotein (LDL) and total antioxidative capacity of plasma were measured in rabbits fed for 6 weeks a cholesterol-rich diet and for further 34 weeks a normal diet. Whereas the time to induce copper ion-mediated lipid peroxidation in LDL was prolonged during hypercholesterolemia, total antioxidative capacity as determined by a radical-trapping assay was increased at 6 weeks, but decreased during the time when the plasma cholesterol levels declined slowly to normal. Since aortic plaque progression was continued also during the first 15 weeks of normal diet, increased atherogenicity of hypercholesterolemia might be better reflected by the antioxidant capacity of plasma rather than by oxidation of isolated LDL.
Assuntos
Antioxidantes/metabolismo , Colesterol na Dieta/metabolismo , Hipercolesterolemia/metabolismo , Hipercolesterolemia/patologia , Lipoproteínas LDL/metabolismo , Plasma/metabolismo , Túnica Íntima/metabolismo , Animais , Antioxidantes/farmacologia , Arteriosclerose/etiologia , Arteriosclerose/metabolismo , Arteriosclerose/patologia , Colesterol na Dieta/efeitos adversos , Técnicas de Cultura , Modelos Animais de Doenças , Masculino , Oxirredução , Coelhos , Valores de Referência , Túnica Íntima/patologiaRESUMO
The aim of the present study was to determine the effect of progesterone on the action of estrogen in the development of atherosclerosis. A total of 48 female New Zealand white (NZW) rabbits were ovariectomized. The animals were separated into 6 groups of 8 animals each and received subsequently a 0.5% cholesterol diet for 12 weeks. During this cholesterol feeding period, either estradiol (1 mg/kg body weight (BW)/week), progesterone (25 mg/kg BW/week), or combined estradiol/progesterone (in above dosages) was administered intramuscularly in each group (n = 8 each) of ovariectomized rabbits. One additional group of 8 animals received a combined estrogen/ progesterone regimen, but with progesterone at one third of the above mentioned dosage. In another 8 rabbits, progesterone was reduced to one ninth of the maximum dosage above, whereas estrogen was kept the same, at 1 mg/kg BW/week. Eight ovariectomized animals served as the control group and received no hormone treatment. After 12 weeks, the animals were sacrificed and the proximal aortic arch was removed for further histological examination. An inhibitory effect of estrogen of intimal thickening was found, in comparison to the control group (intimal area: 0.7 +/- 0.5 mm2 vs. 3.7 +/- 2.5 mm2, P < 0.01), whereas progesterone alone did not show a significant effect on intimal plaque size (intimal area: 4.0 +/- 2.3 mm2). In combination with progesterone (high dose), estrogen was not able to reduce intimal atherosclerosis (intimal area: 3.4 +/- 2.4 mm2). However, the beneficial effect of estrogen was not affected by progesterone, when this was reduced respectively to one third (intimal area: 0.8 +/- 0.7 mm2), or to one ninth of the highest dosage (intimal area: 0.6 +/- 0.4 mm2). Interestingly, these differences in atherosclerotic plaque development were observed without significant changes in plasma cholesterol concentrations by the administered hormones. In conclusion, progesterone was dose-dependently able to completely inhibit the beneficial effect of estrogen in experimental atherosclerosis, suggesting that progesterone exerts a direct inhibitory effect on the athero-protective action of estrogen. In the context of recently published data, the present work confirms the importance of the 'non-lipid-mediated', anti-atherosclerotic effect of estrogen, probably due to an interaction with six hormone receptors in vascular smooth muscle cells (VSMC).
Assuntos
Arteriosclerose/prevenção & controle , Estradiol/análogos & derivados , Antagonistas de Estrogênios/farmacologia , Terapia de Reposição de Estrogênios , Progesterona/farmacologia , Androgênios/sangue , Animais , Aorta/química , Aorta/patologia , Arteriosclerose/sangue , Arteriosclerose/patologia , Colesterol/sangue , Colesterol na Dieta/administração & dosagem , Dieta Aterogênica , Relação Dose-Resposta a Droga , Interações Medicamentosas , Estradiol/administração & dosagem , Estradiol/sangue , Estradiol/farmacologia , Antagonistas de Estrogênios/administração & dosagem , Feminino , Músculo Liso Vascular/efeitos dos fármacos , Músculo Liso Vascular/metabolismo , Ovariectomia , Progesterona/administração & dosagem , Progesterona/sangue , Coelhos , Receptores de Estrogênio/efeitos dos fármacosRESUMO
The effects of intravenous cibenzoline (1.5 mg/kg) on atrial vulnerability and electrophysiology were assessed in 25 patients with documented paroxysmal atrial fibrillation (AF), in whom sustained (greater than 30 seconds) AF was induced by atrial stimulation with up to 2 extrastimuli and paced rates between 100 and 180 beats/min. In 7 patients AF persisted despite the application of cibenzoline, and in 8 patients the induction of sustained AF was prevented by cibenzoline. Intraatrial conduction time, flutter cycle length and shortest ventricular cycle length during AF were increased by cibenzoline (p less than or equal to 0.01). Sinus cycle length was decreased (p less than or equal to 0.05), whereas sinus node recovery time remained unchanged. The effective refractory period of the right atrium was not significantly affected. Eight patients with frequent episodes of paroxysmal AF received oral cibenzoline for control of paroxysmal AF irrespective of the efficacy of intravenous cibenzoline. Prevention of stimulation-induced AF predicted successful treatment of paroxysmal AF (p = 0.018). Cibenzoline could be effective in the treatment of atrial arrhythmias, and selection of an antiarrhythmic therapy for recurrent AF seems to be useful.
Assuntos
Antiarrítmicos/uso terapêutico , Fibrilação Atrial/tratamento farmacológico , Flutter Atrial/tratamento farmacológico , Nó Atrioventricular/efeitos dos fármacos , Sistema de Condução Cardíaco/efeitos dos fármacos , Imidazóis/uso terapêutico , Administração Oral , Fibrilação Atrial/diagnóstico , Flutter Atrial/diagnóstico , Estimulação Cardíaca Artificial , Eletrocardiografia , Eletrofisiologia , Feminino , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-IdadeRESUMO
Chronic estrogen supplementation is known to improve endothelial function in postmenopausal women. We studied the acute effect of a single dose of orally administered 17beta-estradiol valerate (E2) on the peripheral endothelial dependent and independent vasodilatation in postmenopausal women with coronary artery disease (CAD). 20 postmenopausal women (age: 64.9 (7.2) y, height: 1.61 (0.04) m. weight: 68.6 (10.6) kg) with angiographically confirmed CAD were randomly examined for flow-associated vasodilatation (= FAD%, a marker for endothelial dependent vasodilatation) and for glyceryltrinitrate (400 microg, p.o.) induced vasodilatation (= GTN%, representing endothelial independent vasodilatation) two hours after placebo controlled, randomized crossover intake of 4 mg E2 p.o. After placebo FAD% was impaired (3.5 (1.7)%) compared to historic controls. After the oral intake of 4 mg E2, FAD% improved to 5.0 (2.8)% (P=0.02). GTN% was not significantly influenced by the oral E2 (E2: 12.6 (5.7) v placebo: 11.2 (6.9)%, P=0.14). Endothelial dysfunction can partially be restored by a single oral dose of 4 mg E2. This indicates an acute vasoprotective effect of E2 beyond its genomic and lipid modifying actions. It remains to be investigated if estrogen might play a beneficial role in the acute treatment of symptomatic coronary artery disease such as angina pectoris or preinfarct syndrome.
Assuntos
Doença das Coronárias/tratamento farmacológico , Endotélio Vascular/fisiopatologia , Estradiol/análogos & derivados , Estrogênios Conjugados (USP)/uso terapêutico , Pós-Menopausa/fisiologia , Idoso , Pressão Sanguínea/fisiologia , Doença das Coronárias/diagnóstico por imagem , Doença das Coronárias/fisiopatologia , Endotélio Vascular/diagnóstico por imagem , Estradiol/uso terapêutico , Feminino , Humanos , Pessoa de Meia-Idade , Pós-Menopausa/efeitos dos fármacos , Ultrassonografia , Vasodilatação/efeitos dos fármacos , Vasodilatação/fisiologiaRESUMO
BACKGROUND: Because of the beneficial effects of estrogen, premenopausal women are normally protected against coronary heart disease (CHD) and are at lower risk for myocardial infarction; consequently, CHD occurs very rarely in menstrually active women. Given this background, the aim of the present study was to test the hypothesis that decreased concentrations of estrogen are associated with CHD in premenopausal women. METHODS: Fourteen premenopausal women with CHD were investigated and compared with a healthy control group comparable for age and cardiovascular risk factors. Relevant characteristics of patients and controls were assessed: age, blood pressure, body mass index, total cholesterol and high-density lipoprotein cholesterol, triglycerides, former pregnancies, ovariectomy and related surgical interventions, smoking history and former use of oral contraceptives. To ensure the premenopausal status of the participants, the regularity of the menstrual cycle and the follicle-stimulating hormone concentrations were also assessed. Plasma estradiol and progesterone and urine estrone concentrations (24 h urine collection) were measured at day 6 after estimated ovulation to assess the relative increase in plasma estradiol and progesterone during the second half of the menstrual cycle. RESULTS: Compared with the control group, premenopausal women with CHD had significantly lower concentrations of plasma estradiol (408.9 +/- 141 pmol/l and 287.8 +/- 109 pmol/l respectively; P = 0.0228) and total estrogen (2061 +/- 693 pg/mumol creatinine and 1607 +/- 448 pg/mumol creatinine respectively; P = 0.025) in the urine. However, the progesterone concentrations were not significantly different between the groups. These findings might be explained by a partial ovarian dysfunction, as the patient group had a significantly higher number of tubal sterilizations (eight compared with one). CONCLUSION: Our data provide support for the hypothesis that decreased concentrations of estradiol might be an additional pathogenetic factor for the development of CHD in menstrually active premenopausal women.
Assuntos
Doença das Coronárias/sangue , Estradiol/sangue , Pré-Menopausa/sangue , Adulto , Doença das Coronárias/epidemiologia , Doença das Coronárias/etiologia , Estradiol/biossíntese , Estrogênios/urina , Feminino , Humanos , Incidência , Pessoa de Meia-Idade , Valores de Referência , Fatores de Risco , Sensibilidade e EspecificidadeAssuntos
Teste de Esforço , Frequência Cardíaca , Infarto do Miocárdio/fisiopatologia , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
Despite decreasing renal function with increasing age, an elevated level of serum glycoside concentration is not noted in elderly patients after undergoing continuous therapy with 0,2 or 0,3 mg beta-methyldigoxin, 0,4 mg beta-acetyldigoxin or 0,5 mg digoxin respectively, as long as the serum creatinine is still normal. Therefore, it is sufficient to determine the serum creatinine level before initiating glycoside therapy with digoxin or digoxin derivates. As a rule, a continuous oral therapy using 0,2 mg beta-methyldigoxin, 0,3 mg beta-acetyldigoxin or 0,375 mg digoxin can be carried out on elderly patients having a normal serum creatinine level, without risk and without danger of toxic side-effects. There is evidence that glycoside tolerance is decreased in the elderly. In elderly patients with a serum concentration level of 2,3 ng/ml or higher, 87% showed toxic side-effects, whereas in the younger age group only 72% of the patients with equally high serum glycoside concentrations were intoxicated. Therefore, oral doses exceeding 0,2 mg beta-methyl-digoxin, 0,3 mg beta-acetyldigoxin, or 0,375 mg digoxin should be carefully controlled by EKG in elderly patients. The most frequent cause of intoxication in elderly patients (75% of the cases) was an impaired renal function with elevation of the serum creatinine level,--a factor which was not taken into consideration in determining the glycoside dosage.
Assuntos
Digoxina/uso terapêutico , Acetildigoxinas/uso terapêutico , Adulto , Idoso , Digoxina/efeitos adversos , Glicosídeos/sangue , Humanos , Medigoxina/uso terapêutico , Pessoa de Meia-IdadeRESUMO
Today glycosides have 3 indications: manifest and chronic cardiac insufficiency, arrhythmia absoluta and paroxysmal supraventricular tachycardia. Glycosides are no longer important in the therapy of acute cardiac insufficiency. There are also absolute and relative contraindications which should be recognized; in coronary heart disease glycosides should only be used if there is really a latent of manifest cardiac insufficiency.
Assuntos
Glicosídeos Cardíacos/uso terapêutico , Insuficiência Cardíaca/tratamento farmacológico , Potenciais de Ação/efeitos dos fármacos , Nó Atrioventricular/efeitos dos fármacos , Glicosídeos Cardíacos/efeitos adversos , Frequência Cardíaca/efeitos dos fármacos , Humanos , Potenciais da Membrana/efeitos dos fármacos , Contração Miocárdica/efeitos dos fármacos , Taquicardia Paroxística/tratamento farmacológico , Vasodilatadores/uso terapêutico , Fibrilação Ventricular/induzido quimicamenteRESUMO
In a 4-week randomized, double-blind study, 87 patients with essential hypertension received either 10 mg bisoprolol (B) or 100 mg metoprolol (M) once daily (o.d.). The effects of the beta blockers on systolic blood pressure, heart rate and rate-pressure product during exercise, 24 h (E2) and 3 h (E3) after administration (p.a.) were compared with the values obtained in the baseline exercise test (E1). 24 hours p.a. the effects of B were significantly stronger than of M (E1-E2: B vs M; P less than 0.01) whereas 3 h p.a. no significant differences were detectable between B and M. The residual effects 24 h p.a. in relation to the effects 3 h p.a. (E1-E2/E1-E3) were significantly greater with B (86-93%) than with M (53-66%). In contrast to the findings with 100 mg M o.d., 10 mg bisoprolol o.d. guarantees a persistent reduction in exercise blood pressure and heart rate throughout the entire dosage interval of 24 h.
Assuntos
Pressão Sanguínea/efeitos dos fármacos , Teste de Esforço , Frequência Cardíaca/efeitos dos fármacos , Hipertensão/fisiopatologia , Metoprolol/uso terapêutico , Propanolaminas/uso terapêutico , Adolescente , Adulto , Idoso , Bisoprolol , Ensaios Clínicos como Assunto , Método Duplo-Cego , Feminino , Humanos , Hipertensão/tratamento farmacológico , Masculino , Metoprolol/efeitos adversos , Pessoa de Meia-Idade , Propanolaminas/efeitos adversos , Distribuição Aleatória , Descanso , Fatores de TempoRESUMO
Serum glycoside concentration was 2.3 ng/ml or more in 299 patients digitalised with digoxin or digoxin derivatives. Mean serum glycoside concentration was 3.4 +/- 1.3 ng/ml (range 2.3-11.00 ng per ml). Usually, high serum concentrations were associated with advanced den or digoxin-derivative overdosage occurred in only 10% of patients. Almost three quarters of those with intoxication had impaired renal function. There was some evidence that low body-weight increased the potential risk of intoxication.
Assuntos
Digoxina/intoxicação , Arritmias Cardíacas/induzido quimicamente , Peso Corporal , Digoxina/análogos & derivados , Digoxina/sangue , Bloqueio Cardíaco/induzido quimicamente , Humanos , Falência Renal Crônica/complicações , Taquicardia/induzido quimicamenteRESUMO
Flecainide was given to a patient in a dose of 150 mg twice daily to convert a newly developed atrial fibrillation; concomitant therapy was unchanged. After the fourth dose the patient complained of upper abdominal pain and nausea. GOT and GPT, normal at admission to the hospital, became markedly elevated and reached a maximum of 960 IU/I (GOT) and 993 IU/I (GPT) one day later, although the enzymes which indicate cholestasis remained at a normal level or did not increase. On the assumption of a drug-induced allergic reaction, flecainide was withdrawn, after which liver enzymes rapidly returned to control values. Although neither a reexposition with flecainide nor a liver biopsy was obtained, a flecainide-induced hepatitis seems probable.
Assuntos
Estenose da Valva Aórtica/cirurgia , Fibrilação Atrial/tratamento farmacológico , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Flecainida/efeitos adversos , Próteses Valvulares Cardíacas , Complicações Pós-Operatórias/tratamento farmacológico , Flecainida/uso terapêutico , Humanos , Testes de Função Hepática , Masculino , Pessoa de Meia-IdadeRESUMO
In a patient with frequent paroxysmal supraventricular tachycardia, an electrophysiologic study was performed. Although by programmed atrial stimulation only double AV nodal pathways could be documented, three distinct forms of AV nodal reentrant tachycardia could be induced. By programmed atrial stimulation a typical AV nodal reentrant tachycardia was initiated, by programmed ventricular stimulation, an AV nodal reentrant tachycardia was induced with an antegrade conduction time of 215 ms and a retrograde conduction time of 160 ms. Furthermore, a third form of tachycardia was induced with alternating cycle length due to two different antegrade conduction times, whereas retrograde conduction time was almost identical, irrespective of the antegrade conduction time. The patient received betaxolol (20 mg day-1); during a second electrophysiologic study, the tachycardia could not be induced, and it did not occur spontaneously during a follow-up period of 14 months.
Assuntos
Nó Atrioventricular/fisiopatologia , Taquicardia por Reentrada no Nó Atrioventricular/fisiopatologia , Betaxolol/uso terapêutico , Estimulação Cardíaca Artificial , Eletrocardiografia , Humanos , Masculino , Pessoa de Meia-Idade , Taquicardia por Reentrada no Nó Atrioventricular/diagnóstico , Taquicardia por Reentrada no Nó Atrioventricular/tratamento farmacológicoRESUMO
For elucidation of atrial electrophysiology and vulnerability an electrophysiological study was performed in 45 patients with documented paroxysmal atrial fibrillation and a control group (n = 46). Atrial vulnerability was assessed by programmed atrial stimulation with up to two extrastimuli during sinus rhythm and paced cycle lengths of 600 msec, 430 msec and 330 msec. Sustained atrial fibrillation or flutter was induced in 37/45 patients with paroxysmal atrial fibrillation in contrast to 9/46 patients in the control group (P less than 0.001). Left atrial diameter (M-mode echocardiogram), P wave duration, sinus cycle length, sinus node recovery time, and the effective refractory period of the right atrium were not significantly different between the two study groups. Intraatrial conduction time from the high right atrium (HRA) to the basal right atrium (A) and the functional refractory period of the right atrium were significantly longer in patients with paroxysmal atrial fibrillation.
Assuntos
Fibrilação Atrial/fisiopatologia , Flutter Atrial/fisiopatologia , Função Atrial/fisiologia , Estimulação Cardíaca Artificial , Sistema de Condução Cardíaco/fisiopatologia , Fibrilação Atrial/diagnóstico , Flutter Atrial/diagnóstico , Ecocardiografia , Eletrocardiografia , Eletrofisiologia , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
Highly digoxin-specific or ouabain-specific antibodies can readily be obtained by immunizing rabbits or sheep with repeated injections of the glycoside coupled to protein carriers. By virtue of their binding capacity digoxin-specific antibodies are capable of removing digoxin concentrations from red blood cells and renal tissue specimens. As evidenced by various experiments with human erythrocytes and isolated cardiac preparations in vitro, digoxin effects are rapidly reversible in the presence of digoxin-specific antibodies. In vivo antidigoxin antibodies can protect animals from digoxin effects and promptly abolish established toxic effects, associated with marked alterations of digoxin pharmacokinetics. However, due to the large molecular weight, complete antibodies cannot be eliminated via the renal route. The use of antigen-binding (Fab) fragments of digoxin-specific antibodies offer the advantage of rapid renal elimination of bound and inactivated digoxin. So far, due to potential immune reactions, the clinical use of purified digoxin-specific antibodies of Fab fragments is restricted to life-threatening accidental or suicidal digoxin or digitoxin poisoning.
Assuntos
Anticorpos , Glicosídeos Digitálicos/intoxicação , Animais , Formação de Anticorpos , Glicosídeos Digitálicos/sangue , Glicosídeos Digitálicos/metabolismo , Digoxina/imunologia , Digoxina/metabolismo , Cães , Cobaias , Imunização Passiva , Fragmentos Fab das Imunoglobulinas , Rim/metabolismo , Ouabaína/imunologia , Ouabaína/metabolismo , CoelhosRESUMO
The electrophysiologic effects of the beta-1 selective beta adrenergic blocking drug Betaxolol were investigated after intravenous (0.15 mg/kg body weight) and oral (20 mg/day) administration in 11 patients with atrioventricular-nodal reentrant tachycardia. Betaxolol significantly (p less than 0.01) prolonged cycle length, sinus node recovery time, AH-interval, as well as the antegrade functional refractory period of the slow and fast AV-nodal pathway. The effective refractory period of the fast AV-nodal pathway was also markedly increased (p less than 0.05). In only six patients could the effective refractory period of the slow AV-nodal pathway be determined; in the other patients, it was shorter than the effective refractory period of the atrium. The effective refractory period of the atrium and the ventricle was not significantly altered by Betaxolol. Intravenous administration of Betaxolol suppressed induction of tachycardia in eight patients, whereas after oral Betaxolol, tachycardia was not inducible in ten patients. Betaxolol prevented induction of tachycardia in two patients by prolonging antegrade conduction over the slow AV-nodal pathway. The retrograde fast AV-nodal pathway was blocked in eight patients. Presumably the increased effectiveness of oral Betaxolol can be attributed to higher Betaxolol plasma concentrations, reached after oral treatment (58 +/- 38 ng/ml), as compared to intravenous administration (40 +/- 40 ng/ml). There were no false positive results after intravenous testing of Betaxolol.
Assuntos
Nó Atrioventricular/efeitos dos fármacos , Eletrocardiografia , Sistema de Condução Cardíaco/efeitos dos fármacos , Propanolaminas/administração & dosagem , Taquicardia por Reentrada no Nó Atrioventricular/tratamento farmacológico , Taquicardia Supraventricular/tratamento farmacológico , Administração Oral , Adulto , Betaxolol , Pressão Sanguínea/efeitos dos fármacos , Estimulação Cardíaca Artificial , Feminino , Frequência Cardíaca/efeitos dos fármacos , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-IdadeRESUMO
The effectiveness of Cibenzoline was assessed by means of programmed ventricular stimulation in 13 patients with sustained, drug refractory ventricular tachycardia. Besides Cibenzoline, an average of 3.5 antiarrhythmic drugs were tested, or were clinically ineffective. Cibenzoline was applied, i.v., in a dose of 1.5 mg/kg within 10 min. Cycle length was significantly shortened (p less than or equal to 0.05) while increases were noted for effective refractory period of the right ventricle (p less than or equal to 0.05), intranodal (AH-interval) and infranodal (HV-interval) conduction time (p less than or equal to 0.01), QRS-duration (p less than or equal to 0.001), QT-interval corrected for frequency (p less than or equal to 0.001) as well as cycle-length of the tachycardia (p less than or equal to 0.05). After i.v. Cibenzoline, induction of tachycardia was more difficult in two patients and unchanged in five patients. Spontaneous occurrence of the tachycardia was noted in three patients, and in one patient tachycardia was sustained by atrial stimulation. Cibenzoline i.v. prevented tachycardia in two patients respectively induction of tachycardia was not reproducible. It is concluded that Cibenzoline may be effective in individual patients with sustained ventricular tachycardia unresponsive to other antiarrhythmic drugs.